Related Experiment Video
Updated: Jun 26, 2025
Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
Can miRNA Expression Levels Predict Treatment Resistance to Serotonin Reuptake Inhibitors in Patients with
Efruz Pirdoğan Aydın1, Hani Alsaadoni2, Azra Gökovalı Beğenen1
1Department of Psychiatry, University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital, İstanbul, Turkey.
Background:
Obsessive-compulsive disorder is a psychiatric disorder with different clinical manifestations caused by the interaction of genetic and environmental factors. Recently, it has been shown that microRNAs play a role in the pathogenesis of some psychiatric diseases. We aimed to compare the expression levels of microRNAs between obsessive-compulsive disorder patients and healthy controls and investigate the association between miRNA expression levels and treatment resistance.
Methods:
Twelve miRNA expression levels in venous blood of 100 obsessive-compulsive disorder patients and 50 healthy controls were detected by real-time polymerase chain reaction. Patients were assessed using the Hamilton Depression Rating Scale, Yale-Brown Obsessive-Compulsive Scale, and Yale-Brown Obsessive-Compulsive Symptom Checklist. Each patient was scheduled for a monthly follow-up for a minimum 6-month-period after serotonin receptor inhibitor treatments were initiated.
Results:
We found that miR-26a-5p (P < .001), miR-21-3p (P < .001), miR-219a-1-3p (P = .016), miR-106b-5p (P = .039), miR-6740-5p (P = .020), miR-320a (P = .001), miR-22-3p, and miR-16b-5p (P = .010) expression levels were statistically higher in obsessive-compulsive disorder patients than healthy controls; miR-135a-5p (P < .001) and miR-129-6b-5p (P < .001) expression levels were statistically lower. Also, it was determined that increased miR-106b-5p levels were associated with treatment-resistance (P = .020) and there was a negative correlation between miR-374b-3p and disease severity (P = .042).
Conclusion:
In obsessive-compulsive disorder, there may be a potential value in the relationship between various miRNA expression levels and treatment resistance and disease severity, and future studies may be beneficial.
Insights
microRNA (miRNA) levels differ in obsessive-compulsive disorder (OCD) patients compared to controls. Certain miRNA expressions, like miR-106b-5p, are linked to treatment resistance in OCD.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Obsessive-compulsive disorder (OCD) is a complex psychiatric condition influenced by genetic and environmental factors.
- microRNAs (miRNAs) are increasingly recognized for their role in the pathogenesis of psychiatric disorders.
Purpose of the Study:
- To compare miRNA expression levels between individuals with OCD and healthy controls.
- To investigate the association between specific miRNA expression levels and treatment resistance in OCD patients.
Main Methods:
- Real-time polymerase chain reaction was used to quantify the expression of twelve miRNAs in the blood of 100 OCD patients and 50 healthy controls.
- Patients underwent clinical assessments using standardized scales (Hamilton Depression Rating Scale, Yale-Brown Obsessive-Compulsive Scale, Yale-Brown Obsessive-Compulsive Symptom Checklist).
- A 6-month follow-up was conducted after initiating serotonin receptor inhibitor treatments.
Main Results:
- Elevated expression of miR-26a-5p, miR-21-3p, miR-219a-1-3p, miR-106b-5p, miR-6740-5p, miR-320a, miR-22-3p, and miR-16b-5p was observed in OCD patients compared to controls.
- Lower expression of miR-135a-5p and miR-129-6b-5p was found in OCD patients.
- Increased miR-106b-5p levels correlated with treatment resistance (P = .020).
- A negative correlation was found between miR-374b-3p and OCD disease severity (P = .042).
Conclusions:
- Specific miRNA expression profiles may serve as potential biomarkers in obsessive-compulsive disorder.
- The relationship between miRNA expression, treatment resistance, and disease severity warrants further investigation in OCD.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
01:22MicroRNAs